Cara Therapeutic
Yahoo Finance • 11 months ago
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Cara Therapeutics, Inc. – Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce... Full story
Yahoo Finance • last year
Cara Therapeutics Reports Third Quarter 2023 Financial Results
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical programs anticipated within current finan... Full story
Yahoo Finance • last year
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA)... Full story
Yahoo Finance • last year
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today anno... Full story
Yahoo Finance • last year
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today ann... Full story
Yahoo Finance • last year
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today ann... Full story
Yahoo Finance • 2 years ago
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and... Full story
Yahoo Finance • 2 years ago
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALL... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics Reports First Quarter 2023 Financial Results
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by total vial sales more than do... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today annou... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today rel... Full story
Yahoo Finance • 2 years ago
Q4 2022 Cara Therapeutics Inc Earnings Call
Participants Christopher A. Posner; President, CEO & Director; Cara Therapeutics, Inc. Joana Goncalves; Chief Medical Officer; Cara Therapeutics, Inc. Matthew Murphy Ryan D. Maynard; CFO; Cara Therapeutics, Inc. AJ Velasquez-Mao Anna... Full story
Yahoo Finance • 2 years ago
These 2 Stocks Are Plunging After Hours Monday
The stock market was mixed to start the week on Monday, as investors seemed more comfortable waiting to find out what Federal Reserve chair Jerome Powell will say later in the week about the state of the U.S. economy and the central bank's... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including collaborative revenue of $16.6 million... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today anno... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
STAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today anno... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today anno... Full story
Yahoo Finance • 2 years ago
KemPharm Announces Appointment of Christopher Posner as New Independent Director
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Compan... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics Reports Third Quarter 2022 Financial Results
– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA®(difelikefalin) injection – – Strong demand for KORSUVA injection driven by large dialysis organizations with ~180,000 vials shipped – – FDA meeting... Full story
Yahoo Finance • 2 years ago
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today anno... Full story
